[ Nemesis Bioscience raises $908.1K ]
Nemesis Bioscience has raised $908.1K in Seed funding.
Founded in 2014, Nemesis Bioscience develops and commercializes therapeutic agents for clinical, veterinary and industrial sectors. Nemesis Bioscience is advancing Bacterial Cybergenetics technologies in vivo, including: Nemesis Symbiotics for applications including the reversal of antibiotic resistance and Transmids for their clinical, veterinary and industrial delivery.
The company intends to use the funds to validate its suite of technologies.
|Founder / CEO||Frank Massam|
|Investors||Rainbow Seed Fund|